Applies to Employer plans.
Covered with requirementsQualification pathways
You can qualify through any one of these.
Type 2 Diabetes Approval
All of:
- Diagnosis of type 2 diabetes
- Diagnosis confirmed by medical records OR chart notes
Documentation to bring
- Medical records or chart notes confirming type 2 diabetes diagnosis
Policy note: Policy applies to the GLP-1 Agonist class as a group. The named guideline covers Bydureon BCise, Byetta (exenatide), Mounjaro, Ozempic, Rybelsus, Trulicity, and Victoza (liraglutide) under a single shared rule requiring T2DM diagnosis confirmed by medical records or chart notes. No additional step therapy, BMI, A1C, or lifestyle requirements are specified.
Policy effective April 27, 2026 · verified June 5, 2026 · source: Standard Commercial Guidelines 6 1 26 Excerpted · View policy document (PDF)